Systemic amyloidosis is caused by the extracellular deposition of misfolded protein in multiple organs and systems. The two most prevalent amyloid types with common cardiac involvement are immunoglobulin light chain and transthyretin (ATTR) amyloidosis. These can overlap in presentation but differ in diagnostic pathway and therapeutic approaches1; hence, it is crucial to identify the underlying subtype of cardiac amyloidosis. In this review, we discuss the clinical clues that should raise suspicion for cardiac amyloidosis (CA) in patients presenting in outpatient settings, and we provide a patient-centered diagnostic workup that ensures an accurate diagnosis (Figure 1).
Light chain amyloidosis (AL-CA) is caused by sporadic deposition of kappa or lambda light chains in tissue and therefore does not follow any known inheritance pattern. The disease is one of the plasma cell dyscrasias and found in 10% of patients with multiple myeloma.2 AL-CA is relatively uncommon, with an incidence of 3 to 9 per million person-years.3 Across all forms of amyloidosis, misfolded proteins are often more prevalent in older individuals, possibly due to the changes in physiological microenvironments seen with aging.1 The age at diagnosis varies, although the mean age of AL-CA diagnosis is approximately 57 years old.4,5 AL-CA is historically more readily recognized compared to ATTR, often with a wide-ranging presentation depending on which organ is involved. Symptoms may include heart failure, weight loss, nephrotic syndrome, macroglossia, and GI disturbances, among others.6
Transthyretin is a thyroxine and retinol transport protein predominantly produced in the liver, choroid plexus, and retina and is found circulating in plasma and cervical spinal fluid.7 ATTR amyloidosis can result from an amino acid change, leading to variants (ATTRv) that precipitate transthyretin tetramer instability, or can occur despite having normal protein structure, as in wild type ATTR (ATTRwt).8 These two types are closely related in pathophysiology, both showing deposition of fibrils in different organs and systems, but the distinction comes in their presentation and currently available therapies.
As the name suggests, ATTRwt is a sporadic disease of older individuals, most often seen in White males, with prevalence increasing significantly (12-25%) in people over 80 years.9 ATTRwt predominantly presents as heart failure with features of restrictive and infiltrative cardiomyopathy, with additional history clues including orthopedic manifestations such as prior carpal tunnel release, spinal stenosis, and neuropathy.10 ATTRv is inherited through an autosomal dominant pattern with over 100 different associated variants.11 The severity, age of onset, and symptomology of the disease is dependent on the particular variant and geographical location.12 In ATTRv, early onset is considered before the age of 50, and incidence varies geographically in endemic versus nonendemic areas.13,14 In the United States, there is a higher prevalence of the p.Val142Ile mutation among people of African and Afro-Caribbean ancestry but with variable penetrance.15 This mutation is of particular interest given its prevalence and predominantly cardiac phenotype.16,17 Overall, ATTRv has a rather heterogeneous presentation depending on the underlying variant and can emerge with a polyneuropathy phenotype, cardiomyopathy phenotype, or mixed.6,18
Due to the varying and at times nonspecific symptomatology in patients with amyloidosis, it is important to pay attention to minor clues in a patient’s history, such as previous orthopedic or neurological conditions that were present years prior to presentation, and carefully evaluate left ventricular hypertrophy (LVH) even in the presence of hypertension. Table 1 summarizes extracardiac symptoms and disease manifestations that should alert the clinician to consider amyloidosis in the differential.19,20,21
|PRESENTATION||AL AMYLOID||ATTR AMYLOID|
|Purpura (periorbital, neckline)||✔||—|
|Autonomic dysfunction (intestinal motility/orthostatic hypotension)||✔||✔*|
|Carpal tunnel syndrome (often bilateral)||—||✔|
|Biceps tendon rupture||—||✔|
|Lumbar spinal stenosis||—||✔|
|Unexplained weight loss (dysphagia, malabsorption)||✔||✔|
In the cardiac phenotype, amyloidosis can cause a wide range of presentations; however, the classic presentation is often cardiomyopathy with restrictive hemodynamics and heart failure.22 The cardiac phenotype typically starts with subclinical extracellular deposition of amyloid fibrils, with progressive increase in ventricular wall thickness, atrial dilatation, arrhythmias, and conduction system abnormalities.20,23 The cardiac phenotype is the leading cause of mortality, with varying survival rates depending on the stage of cardiac involvement.24 For example, in untreated advanced AL-CA, the mean survival is less than 6 months after development of heart failure.25 Early recognition of cardiac involvement in amyloidosis is vital given the high morbidity and mortality coupled with therapeutics that frequently halt the progression of disease but do not reverse it.22
Perhaps the most important aspect is developing a systematic approach to evaluating systemic signs, symptoms, and diagnostic findings that could provide clues to the diagnosis, which, in the era of electronic medical record systems, can be integrated as a systematic checklist for every new patient with heart failure. Table 2 provides some clues from cardiac involvement in amyloidosis.17,19,20,26,27,28,29,30,31,32
|Unexplained weight loss, fatigue, cachexia|
|Progressive decline of blood pressure, or the need for less anti-hypertensive medications over time|
|Inability to tolerate standard heart failure therapies (BB, ACEi/ARB, ARNI) or rate control strategy in atrial fibrillation|
|Left ventricular hypertrophy particularly when associated with relative apical sparing pattern on global longitudinal strain analysis|
|Restrictive diastolic filling pattern|
|Left ventricular ejection fraction to global longitudinal strain ratio (LVEF/GLS) > 4.1|
|Mitral annular tissue Doppler S’ < 6 cm/s|
|Left ventricular ejection fraction 50% ± 5%|
|Low QRS voltage to LV mass ratio|
|Thickening of aortic and mitral valves and intra-atrial septum|
|Average apical/basal longitudinal strain ratio > 2|
|Normal/small LV cavity size|
|Low voltage (QRS < 1 mV in precordial and < 0.5 mV in extremity leads)|
|Pseudoinfarct patterns without known prior MI (QS waves in any two consecutive leads)|
While the sensitivity and specificity of electrocardiograms for cardiac amyloidosis diagnosis is low, the combination of red flags from the patient’s history and electrocardiogram, in the setting of LV hypertrophy, should prompt an evaluation for cardiac amyloidosis.33,34 A history of hypertension should not discourage such an evaluation since hypertension is common in patients with a history of ATTR.35 Once clinical suspicion is raised, pretest probability should drive targeted evaluation.
Coexistent aortic stenosis (AS) and ATTR cardiomyopathy (ATTR-CM) is a relatively recent finding, and there are no mechanistic studies to directly explain the high prevalence of ATTR-CM in AS.30,36 The coexistence of these conditions represents a unique challenge since AS can also lead to increased LV wall thickness and abnormal strain pattern. However, this also represents a unique opportunity to apply screening for red flags in patients presenting with AS, akin to those presenting with heart failure, to identify those with underlying ATTR-CM (Table 2). This is especially important given the comparable mortality between AS patients who underwent transcatheter aortic valve replacement (TAVR) and patients with AS and ATTR-CM who underwent TAVR without other treatments for ATTR-CM.37 Nitsche et al. recently reported on a clinical risk score that can be used to identify ATTR-CM by narrowing down red flags, which include carpal tunnel syndrome, right bundle branch block, ≥ 85 years of age, elevated high sensitivity troponin T ≥ 20 ng/L, having an interventricular septum thickness ≥ 18 mm, E/A ratio ≥ 1.4, and, when feasible to perform, a Sokolow index < 1.9 millivolt.38 Ultimately, the message is to recognize that ATTR-CM coexists with AS, and an evaluation for ATTR-CM red flags in all patients with AS is necessary to improve the care of such patients, especially given the availability of therapeutics.
Currently, no single laboratory test can definitively rule in or out cardiac amyloidosis. When used within the clinical context, elevated N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in patients with stable symptoms in the nonacute setting can be a red flag when it is discrepant with New York Heart Association (NYHA) class. Similarly, chronically elevated troponin is a marker of subclinical myocardial injury and, in the absence of other explanation, should prompt workup for amyloidosis in the presence of LVH.39,40 These markers, in addition to glomerular filtration rate, are the backbone of prognostic models in both AL-CA and ATTR-CM.41,42,43,44
Additionally, with the overlap between AL and ATTR presentation, it is important to rule out AL-CA via laboratory studies early in the evaluation, although at times, for practicality purposes, ruling out AL and obtaining technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy occur simultaneously. All patients with CA phenotype should undergo direct serum and urine immunofixation electrophoresis and light chain quantification to screen for AL-CA with a > 95% sensitivity.45,46 Local teams should work with their respective labs to ensure that direct immunofixation is performed on all samples, irrespective of the results of protein electrophoresis, rather than only as a reflex immunofixation to samples with abnormal protein electrophoresis. It should be noted that patients with ATTR-CM have a high prevalence of monoclonal gammopathy of undetermined significance (MGUS, defined by any abnormalities in the previously mentioned laboratory work), and this should prompt careful evaluation in conjunction with a hematologist to rule out AL-CA and risk stratify MGUS.45,47,48 Light chains are renally cleared, and in the setting of chronic kidney disease, both kappa and lambda light chain levels are elevated (kappa > lambda), which led to the introduction of a “renal” free light chain ratio to account for alterations in renal clearance in these patients.49,50,51 Given the complexities of patients presenting with CA, a granular evaluation of these patients is still indicated.
In ATTR-CM, transthyretin (formerly known as prealbumin) levels can be useful for risk stratification and show early promise for assessing treatment response in patients on tafamidis.52,53 Additionally, retinol binding protein 4, which binds to the transthyretin tetramer, has shown diagnostic potential when combined with additional clinical factors in identifying p.Val142Ile ATTRv-CM.54
The two most common imaging modalities used after echocardiography in the workup of LVH are cardiac magnetic resonance imaging (CMR) and bone scintigraphy (specifically Tc-99m PYP, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid, and Tc-99m hydroxy-methyl-diphosphonate). CMR can be viewed as part of the routine workup of patients with LVH or can be specifically used in the workup of patients with suspected CA. Pretest probability should guide which imaging test to pursue after echocardiography. In patients who have undifferentiated LVH or appear to be at low to intermediate suspicion of CA, CMR is the appropriate next step in evaluating LVH. In patients who have clear high pretest probability for ATTR-CM based on clinical and echocardiographic evaluation, bone scintigraphy is used to confirm ATTR-CM after ruling out AL amyloid cardiomyopathy.55
CMR provides a wealth of cardiac data including anatomy, function, and tissue characterization, with the constellation of findings being highly sensitive and specific for detecting CA.56 Aside from the typical features that can be seen, two main CMR sequences provide diagnostic and mechanistic understanding into the underlying burden of disease.
In amyloidosis, LGE is reflective of amyloid fibrils occupying the extracellular space and the associated subendocardial fibrosis.57 The presence and pattern of LGE provides important diagnostic clues to the extent of CA. The main LGE patterns are diffuse subendocardial LGE and transmural LGE. A common issue when performing LGE imaging is abnormal gadolinium kinetics, where the myocardium and blood T1 values are similar because of high myocardial uptake and fast blood pool washout, which makes it harder to null the myocardium for acquisition of phase-sensitive inversion recovery sequences.58 Although abnormal gadolinium kinetics can provide diagnostic clues, it can cause confusion in interpreting the images due to poor LGE technique (Figure 2A-F). Routine use of native T1 mapping and extracellular volume (ECV) quantification can rescue these shortcomings (Figure 2G).
Progressive amyloid fiber deposition leads to progressive expansion of the extracellular space, which can be estimated using CMR. Native T1 mapping can offer clues regarding the presence of CA without using gadolinium.59 ECV, which requires both native and post-gadolinium T1 map, can also be used as a surrogate for total amyloid mass in the myocardium.60 Rarely, certain early amyloidosis phenotypes, especially in patients with hereditary ATTR, can present without significant LVH and with minimal or absent LGE but with elevated T1 mapping and ECV (Figure 3). Hence, one should always attempt to acquire these sequences in patients referred with LVH or suspicion for CA.
It is worth noting that CMR cannot differentiate between subtypes of CA. Based on the recent multisocietal expert consensus recommendations for multimodality imaging in CA, typical imaging findings of CA on CMR should be accompanied by either histological confirmation (cardiac or extra-cardiac) or by bone scintigraphy and laboratory studies for AL-CA.61
The resurrection of Tc-99m PYP scintigraphy and a subsequent multicenter study in 2016 have revolutionized the approach to diagnosing ATTR-CM.62 While planar imaging has been historically used, recent advances have shown how myocardial single-photon emission computed tomography (SPECT) imaging is essential to define myocardial involvement and exclude false positive scans due to blood pooling of the tracer.63,64,65 In addition, SPECT/computed tomography in particular provides excellent anatomical landmarks that help differentiate blood pooling versus myocardial uptake in milder and regional forms of tracer uptake.66 Despite its limitations, in a population with a high clinical pre-test probability for ATTR-CM, grades 2 to 3 on planar imaging combined with a negative serum evaluation for AL-CA yield a 100% positive predictive value.55 The use of Tc-99m PYP with SPECT can be a successful strategy in making a nontissue diagnosis of ATTR-CM when clear diffuse uptake of the tracer is present. In all other atypical imaging findings, supportive evidence should be sought from other imaging tests or tissue biopsy to avoid misdiagnosis of ATTR-CM.
Historically, endomyocardial biopsy was required to diagnose and subtype cardiac amyloidosis. With advances in diagnostic imaging and evaluation of CA, endomyocardial biopsy is not required routinely for ATTR-CM patients. Biopsy in ATTR-CM is indicated in the following cases: (1) when one cannot reliably differentiate between AL and ATTR-CM, such as abnormal monoclonal protein workup in elderly individuals who are at risk for ATTR-CM or in conjunction with abnormal bone scintigraphy; (2) when imaging has atypical findings, such as borderline or negative nuclear scintigraphy in suspected patients with ATTR-CM; or (3) to evaluate for other less common forms of amyloidosis. In AL-CA, endomyocardial biopsy is more frequently required in the absence of histological confirmation from an extra-cardiac site. The demonstration of Congo red stained extracellular amorphous material in the presence of an amyloid clinical phenotype is diagnostic of the disease, with mass spectroscopy providing unique capabilities of subtyping the amyloid protein.67
In patients deemed to have ATTR-CM, transthyretin gene sequencing is essential to differentiate ATTRv-CM from ATTRwt-CM. It is vital to differentiate between the two subtypes because there are implications with regard to understanding disease severity, family screening, and utilization of approved therapies.22,68,69 If a patient is genotype positive for a pathogenic variant, it is vital to provide genetic counseling and assess family members either for the phenotype or via cascade genetic screening. ATTRv has an autosomal dominant inheritance pattern that is age dependent with variable penetrance.11 Each pathogenic variant has its own unique biochemical effects and phenotype. Generally, it is recommended to start genetic testing at least 10 years prior to the onset of clinical disease in a family member or earlier if signs of clinical disease appear.1
Cardiac amyloidosis, particularly ATTR-CM, is common in elderly patients with heart failure. Red flags exist and can be systematically incorporated into one’s own practice as simple screening tools to improve the pretest probability. It is essential to differentiate ATTR-CM from AL-CA given the vastly different treatment approach. As the noninvasive diagnosis of CA continues to evolve, improvement in the diagnosis rate of ATTR-CM with less reliance on endomyocardial biopsy as well as availability of novel therapeutics promise a better future for patients living with ATTR-CM.
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Houston Methodist designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Click to earn CME credit: https://cvent.me/0KEEPx.
Ahmad Masri receives research grants from Pfizer, Ionis, Akcea, and Ultromics and fees from Eidos, Pfizer, Ionis, Akcea, Alnylam, Cytokinetics, BMS, Tenaya and Attralus. There are no other disclosures.
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554–1568. doi: https://doi.org/10.1093/eurheartj/ehab072
Hasserjian RP, Goodman HJB, Lachmann HJ, Muzikansky A, Hawkins PN. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology. 2007 Apr;50(5):567–73. doi: https://doi.org/10.1111/j.1365-2559.2007.02658.x
Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol. 2016;135(3):172–90. doi: https://doi.org/10.1159/000443200
Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar;27(3):1097–101. doi: https://doi.org/10.1093/ndt/gfr381
McCausland KL, White MK, Guthrie SD, et al. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. Patient. 2018 Apr;11(2):207–216. doi: https://doi.org/10.1007/s40271-017-0273-5
Nienhuis HLA, Bijzet J, Hazenberg BPC. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10–9. doi: https://doi.org/10.1159/000444206. Epub 2016 Feb 25. doi: 10.1159/000444206
Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5566–71. doi: https://doi.org/10.1073/pnas.091431798
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583–96. doi: https://doi.org/10.1056/NEJMra023144
Nakagawa M, Sekijima Y, Yazaki M, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23(1):58–63. doi: https://doi.org/10.3109/13506129.2015.1135792
Aus dem Siepen F, Hein S, Prestel S, et al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019 Dec;108(12):1324–1330. doi: https://doi.org/10.1007/s00392-019-01467-1
Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016 Feb;29 Suppl 1(Suppl 1):S3–S13. doi: https://doi.org/10.1097/WCO.0000000000000288
Mariani L-L, Lozeron P, Théaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015 Dec;78(6):901–16. doi: https://doi.org/10.1002/ana.24519
Waddington-Cruz M, Ackermann EJ, Polydefkis M, et al. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018 Sep;25(3):180–188. doi: https://doi.org/10.1080/13506129.2018.1503593
Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, et al. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid. 2020 Dec;27(4):259–265. doi: https://doi.org/10.1080/13506129.2020.1794807
Chandrashekar P, Alhuneafat L, Mannello M, et al. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circ Genom Precis Med. 2021 Oct;14(5):e003356. doi: https://doi.org/10.1161/CIRCGEN.121.003356
Shah KB, Mankad AK, Castano A, et al. Transthyretin Cardiac Amyloidosis in Black Americans. Circ Heart Fail. 2016 Jun;9(6):e002558. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.115.002558
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan;28(1):10–21. doi: https://doi.org/10.1016/j.tcm.2017.07.004
Perlini S, Mussinelli R, Salinaro F. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. Curr Heart Fail Rep. 2016 Dec;13(6):267–272. doi: https://doi.org/10.1007/s11897-016-0311-y
Ihne S, Morbach C, Sommer C, Geier A, Knop S, Störk S. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. Dtsch Arztebl Int. 2020 Mar 6;117(10):159–166. doi: https://doi.org/10.3238/arztebl.2020.0159
Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30–s35. doi: https://doi.org/10.7861/clinmedicine.18-2-s30
Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012 Jul;26(4):137–54. doi: https://doi.org/10.1016/j.blre.2012.03.001
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007–1016. doi: https://doi.org/10.1056/NEJMoa1805689
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27;112(13):2047–60. doi: https://doi.org/10.1161/CIRCULATIONAHA.104.489187
Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012 Sep 4;126(10):1286–300. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.078915
Pennell DJ, Maceira AM. Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2009 Dec;2(12):1378–80. doi: https://doi.org/10.1016/j.jcmg.2009.10.001
Dispenzieri A, Merlini G. Immunoglobulin Light Chain Systemic Amyloidosis. Cancer Treat Res. 2016;169:273–318. doi: https://doi.org/10.1007/978-3-319-40320-5_15
Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004 Feb 4;43(3):410–5. doi: https://doi.org/10.1016/j.jacc.2003.08.043
Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020 Apr 27;28:100519. doi: https://doi.org/10.1016/j.ijcha.2020.100519
Pagourelias ED, Mirea O, Duchenne J, et al. Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. Circ Cardiovasc Imaging. 2017 Mar;10(3):e005588. doi: https://doi.org/10.1161/CIRCIMAGING.116.005588
Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879–2887. doi: https://doi.org/10.1093/eurheartj/ehx350
Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982 Jan;49(1):9–13. doi: https://doi.org/10.1016/0002-9149(82)90270-3
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15;95(4):535–7. doi: https://doi.org/10.1016/j.amjcard.2004.10.028
Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014 Oct 1;114(7):1089–93. doi: https://doi.org/10.1016/j.amjcard.2014.07.026
Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013 May;18(3):271–80. doi: https://doi.org/10.1111/anec.12036
Dungu JN, Papadopoulou SA, Wykes K, et al. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. Circ Heart Fail. 2016 Sep;9(9):e003352. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003352
Treibel TA, Fontana M, Gilbertson JA, et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016 Aug;9(8):e005066. doi: https://doi.org/10.1161/CIRCIMAGING.116.005066
Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2021 Feb;23(2):250–258. doi: https://doi.org/10.1002/ejhf.1974
Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2021 Jan 19;77(2):128–139. doi: https://doi.org/10.1016/j.jacc.2020.11.006
Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018 Feb;5(1):27–35. doi: https://doi.org/10.1002/ehf2.12203
Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12–26. doi: https://doi.org/10.3949/ccjm.84.s3.02
Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014–20. doi: https://doi.org/10.1016/j.jacc.2016.06.033
Kreusser MM, Volz MJ, Knop B, et al. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clin Res Cardiol. 2020 Jun;109(6):700–713. doi: https://doi.org/10.1007/s00392-019-01559-y
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751–7. doi: https://doi.org/10.1200/JCO.2004.03.029
Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799–2806. doi: https://doi.org/10.1093/eurheartj/ehx589
Bonderman D, Pölzl G, Ablasser K, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020 Dec;132(23–24):742–761. doi: https://doi.org/10.1007/s00508-020-01781-z
Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009 Mar;55(3):499–504. doi: https://doi.org/10.1373/clinchem.2008.117143
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872–2891. doi: https://doi.org/10.1016/j.jacc.2019.04.003
Phull P, Sanchorawala V, Connors LH, et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar;25(1):62–67. doi: https://doi.org/10.1080/13506129.2018.1436048
Singh G. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate. Am J Clin Pathol. 2016 Aug;146(2):207–14. doi: https://doi.org/10.1093/ajcp/aqw099
Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol. 2009 Feb;131(2):166–71. doi: https://doi.org/10.1309/AJCPR2M4EUYNHLGM
Marshall G, Tate J, Mollee P. Borderline high serum free light chain kappa/lambda ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol. 2009 Aug;132(2):309. doi: https://doi.org/10.1309/AJCP8VOT5TVLAQBQ
Hanson JLS, Arvanitis M, Koch CM, et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018 Feb;11(2):e004000. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.117.004000
Saith SE, Gamino D, Teruya S, et al. Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. Amyloid. 2021 Dec;28(4):267–268. doi: https://doi.org/10.1080/13506129.2021.1904390
Arvanitis M, Koch CM, Chan GG, et al. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. JAMA Cardiol. 2017 Mar 1;2(3):305–313. doi: https://doi.org/10.1001/jamacardio.2016.5864
Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404–12. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.021612
Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019 Oct;6(5):1041–1051. doi: https://doi.org/10.1002/ehf2.12511
Pucci A, Aimo A, Musetti V, et al. Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. J Am Heart Assoc. 2021 Oct 19;10(20):e020358. doi: https://doi.org/10.1161/JAHA.120.020358
Maceira AM, Joshi J, Prasad SK. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18;111(2):186–93. doi: https://doi.org/10.1161/01.CIR.0000152819.97857.9D
Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):69–80. doi: https://doi.org/10.1016/j.jcmg.2019.03.026
Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017 Jul 25;70(4):466–477. doi: https://doi.org/10.1016/j.jacc.2017.05.053
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. Circ Cardiovasc Imaging. 2021 Jul;14(7):e000030. doi: https://doi.org/10.1161/HCI.0000000000000029
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195–201. doi: https://doi.org/10.1161/CIRCIMAGING.112.000132
Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021 Jun;14(6):1221–1231. doi: https://doi.org/10.1016/j.jcmg.2020.08.027
Alexander KM, Masri A. Recipe for Success in Transthyretin Cardiomyopathy: Monoclonal Protein Rule Out, SPECT Imaging, and Genetic Testing. JACC Cardiovasc Imaging. 2021 Jun;14(6):1232–1234. doi: https://doi.org/10.1016/j.jcmg.2020.09.009
Masri A, Bukhari S, Ahmad S, et al. Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2020 Feb;13(2):e010249. doi: https://doi.org/10.1161/CIRCIMAGING.119.010249
Duvall WL, Godoy Rivas C, Elsadany M, Hobocan M, Mcmahon S. The use of a novel method for SPECT/CT quantification of 99m-Tc-PYP uptake in the evaluation of ATTR cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2021 Jul 20;22(Suppl 3). doi: https://doi.org/10.1093/ehjci/jeab111.075
Dasari S, Theis JD, Vrana JA, et al. Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc. 2020 Sep;95(9):1852–1864. doi: https://doi.org/10.1016/j.mayocp.2020.06.029
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11–21. doi: https://doi.org/10.1056/NEJMoa1716153
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22–31. doi: https://doi.org/10.1056/NEJMoa1716793